Please do not leave this page until complete. This can take a few moments.
Biotechnology firm Hyperfine Inc., an emerging growth company based in Guilford, announced Wednesday that it is cutting about 14% of its global workforce amid widening losses.
Two bills proposed in the 2025 legislative session seek to create or expand economic development zones in the town of Plainville.
A Westport-based startup that applies artificial intelligence to biomedical research has received a $4 million investment.
State health regulators said Friday they have reached an agreement that will allow for the development of a second proton beam therapy center in Connecticut.
Azitra Inc., a Branford-based biopharmaceutical firm, has announced the pricing for a public offering of its common stock.
Normunity Inc., a biotech creating anti-cancer immunotherapies, announced Monday it has closed a $75 million Series B financing round.
A New Haven-based biotech company, Nema Health, announced a $14.5 million Series A funding round that will expand its online trauma therapy program to three new states: California, Florida and Pennsylvania.
A clinical-stage pharmaceutical company based in Essex, Thetis Pharmaceuticals LLC, has secured $9 million in funding in the form of a loan from The Leona M. and Harry B. Helmsley Charitable Trust.
Three C-level officials at New Haven-based biopharmaceutical company BioXcel Therapeutics Inc.
Quantum-Si Inc., a Branford-based biotech company, is raising $50 million in a registered direct offering of its Class A common stock.
Nuritas, a biotech firm with its U.S. headquarters in New Haven, announced Friday it has closed an oversubscribed $42 million Series C funding round.
Several months after New Haven bioscience company Arvinas Inc.
A Dutch provider of cleanroom and controlled environment facilities, SRBA Group, has acquired a majority interest in a Brookfield-based commercial construction company.
GeneDx, a Stamford-based genomic testing firm formerly known as Sema4, saw its stock price jump nearly 40% in early morning trading on Tuesday as the company touted its first-ever adjusted quarterly profit.
The old saying is, “If at first you don’t succeed, try, try again.” But what if at first you do succeed … say, to the tune of $13 billion? Meet Biohaven 2.0.
Wellinks Inc., a New Haven-based digital healthcare firm, said Monday it has acquired San Francisco-based medical device and data company Spire Health in a non-cash transaction.